Vaccines and antibodies are currently effective intervention strategies for preventing and treating COVID-19. Angiotensin-converting enzyme 2 (ACE2), a primary binding receptor for SARS-CoV-2, is a potential target for the prevention and treatment of COVID-19. At present, therapeutics based on the strategies that block the binding of SARS-CoV-2 Spike protein to the ACE2 receptor have entered clinical trials. On December 5, 2022, the journal Nature published the results of a pharmacological intervention to downregulate ACE2 expression for prevention of SARS-CoV-2 infections. The study found that a nuclear receptor, farnesoid X receptor for bile acids, regulated ACE2 expression. The clinical drug ursodeoxycholic acid that was used to treat liver diseases could downregulate ACE2 expression and prevent SARS-CoV-2 infections, showing a new potential pathway in managing COVID-19.
Citation：
CHEN Zhuo, YANG Hao. Advances in targeted blocking of angiotensin-converting enzyme 2 receptor for prevention of SARS-CoV-2 infection. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(1): 36-38. doi: 10.7507/1007-9424.202212032
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet, 2022, 399(10334): 1513-1536.
|
| 2. |
Hikmet F, Méar L, Edvinsson Å, et al. The protein expression profile of ACE2 in human tissues. Mol Syst Biol, 2020, 16(7): e9610. doi: 10.15252/msb.20209610.
|
| 3. |
Jia H, Neptune E, Cui H. Targeting ACE2 for COVID-19 Therapy: opportunities and challenges. Am J Respir Cell Mol Biol, 2021, 64(4): 416-425.
|
| 4. |
Jin S, He X, Ma L, et al. Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. Nat Commun, 2022, 13(1): 5204. doi: 10.1038/s41467-022-32957-y.
|
| 5. |
Brevini T, Maes M, Webb GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature, 2022 Dec 5. doi: 10.1038/s41586-022-05594-0.
|
| 6. |
Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science, 2021, 371(6531): 839-846.
|
| 7. |
Gao X, Zhang S, Gou J, et al. Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. J Infect, 2022, 85(4): 418-427.
|
| 8. |
Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol, 2020, 17(9): 543-558.
|
- 1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet, 2022, 399(10334): 1513-1536.
- 2. Hikmet F, Méar L, Edvinsson Å, et al. The protein expression profile of ACE2 in human tissues. Mol Syst Biol, 2020, 16(7): e9610. doi: 10.15252/msb.20209610.
- 3. Jia H, Neptune E, Cui H. Targeting ACE2 for COVID-19 Therapy: opportunities and challenges. Am J Respir Cell Mol Biol, 2021, 64(4): 416-425.
- 4. Jin S, He X, Ma L, et al. Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. Nat Commun, 2022, 13(1): 5204. doi: 10.1038/s41467-022-32957-y.
- 5. Brevini T, Maes M, Webb GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature, 2022 Dec 5. doi: 10.1038/s41586-022-05594-0.
- 6. Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science, 2021, 371(6531): 839-846.
- 7. Gao X, Zhang S, Gou J, et al. Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. J Infect, 2022, 85(4): 418-427.
- 8. Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol, 2020, 17(9): 543-558.
